Chemomab Therapeutics (NASDAQ:CMMB) Price Target Raised to $7.00

Chemomab Therapeutics (NASDAQ:CMMB) had its price target lifted by Maxim Group from $4.00 to $7.00 in a research note issued to investors on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

Separately, Oppenheimer reiterated an “outperform” rating and set a $11.00 target price (down previously from $13.00) on shares of Chemomab Therapeutics in a research report on Friday, November 15th.

Chemomab Therapeutics Stock Performance

Shares of Chemomab Therapeutics stock opened at $1.71 on Thursday. The firm has a fifty day moving average of $1.97 and a two-hundred day moving average of $1.71. The stock has a market capitalization of $24.56 million, a price-to-earnings ratio of -1.71 and a beta of 0.66. Chemomab Therapeutics has a 52 week low of $0.58 and a 52 week high of $2.55.

Institutional Trading of Chemomab Therapeutics

A number of large investors have recently made changes to their positions in the company. Sphera Funds Management LTD. bought a new stake in shares of Chemomab Therapeutics in the 3rd quarter valued at $1,907,000. XTX Topco Ltd increased its position in shares of Chemomab Therapeutics by 63.8% in the 4th quarter. XTX Topco Ltd now owns 24,929 shares of the company’s stock valued at $45,000 after buying an additional 9,706 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in shares of Chemomab Therapeutics in the 4th quarter valued at $26,000. Institutional investors own 46.05% of the company’s stock.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).